From fly wings to targeted cancer therapies: A centennial for notch signaling

Cancer Cell

Volumn 25, Issue 3, 2014, Pages 318-334

  Ntziachristos, Panagiotis ^a,b   Lim, Jing Shan ^c   Sage, Julien ^c   Aifantis, Iannis ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; B CELL LEUKEMIA; BREAST CANCER; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DROSOPHILA MELANOGASTER; FORELIMB; HUMAN; LIVER CANCER; LUNG CANCER; LYMPHOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; MYELOMONOCYTIC LEUKEMIA; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; T CELL LYMPHOMA; ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LYMPHOMA; CANCER RESEARCH; NONHODGKIN LYMPHOMA; NUCLEAR LOCALIZATION SIGNAL; PHASE 1 CLINICAL TRIAL (TOPIC); TRANSACTIVATION;

DROSOPHILA MELANOGASTER;

ANIMALS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; DROSOPHILA MELANOGASTER; HUMANS; IMMUNOGLOBULIN J RECOMBINATION SIGNAL SEQUENCE-BINDING PROTEIN; NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84896082963     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.02.018     Document Type: Review

References (233)

1. Agrawal N., Jiao Y., Bettegowda C., Hutfless S.M., Wang Y., David S., Cheng Y., Twaddell W.S., Latt N.L., Shin E.J., et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2012, 2:899-905.
2. Aifantis I., Raetz E., Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat. Rev. Immunol. 2008, 8:380-390.
3. Akhoondi S., Sun D., von der Lehr N., Apostolidou S., Klotz K., Maljukova A., Cepeda D., Fiegl H., Dafou D., Marth C., et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007, 67:9006-9012.
4. Allen T.D., Rodriguez E.M., Jones K.D., Bishop J.M. Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. Cancer Res. 2011, 71:6010-6018.
5. Asnafi V., Buzyn A., Le Noir S., Baleydier F., Simon A., Beldjord K., Reman O., Witz F., Fagot T., Tavernier E., et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009, 113:3918-3924.
6. Asnaghi L., Ebrahimi K.B., Schreck K.C., Bar E.E., Coonfield M.L., Bell W.R., Handa J., Merbs S.L., Harbour J.W., Eberhart C.G. Notch signaling promotes growth and invasion in uveal melanoma. Clin. Cancer Res. 2012, 18:654-665.
7. Aster J.C., Blacklow S.C. Targeting the Notch pathway: twists and turns on the road to rational therapeutics. J.Clin. Oncol. 2012, 30:2418-2420.
8. Avila J.L., Troutman S., Durham A., Kissil J.L. Notch1 is not required for acinar-to-ductal metaplasia in a model of Kras-induced pancreatic ductal adenocarcinoma. PLoS ONE 2012, 7:e52133.
9. Ayyanan A., Civenni G., Ciarloni L., Morel C., Mueller N., Lefort K., Mandinova A., Raffoul W., Fiche M., Dotto G.P., Brisken C. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc. Natl. Acad. Sci. USA 2006, 103:3799-3804.
10. Babaei-Jadidi R., Li N., Saadeddin A., Spencer-Dene B., Jandke A., Muhammad B., Ibrahim E.E., Muraleedharan R., Abuzinadah M., Davis H., et al. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. J.Exp. Med. 2011, 208:295-312.
11. Bailey J.M., Alsina J., Rasheed Z.A., McAllister F.M., Fu Y.Y., Plentz R., Zhang H., Pasricha P.J., Bardeesy N., Matsui W., et al. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterology 2014, 146:245-256.
12. Bajaj J., Maliekal T.T., Vivien E., Pattabiraman C., Srivastava S., Krishnamurthy H., Giri V., Subramanyam D., Krishna S. Notch signaling in CD66+ cells drives the progression of human cervical cancers. Cancer Res. 2011, 71:4888-4897.
13. Balint K., Xiao M., Pinnix C.C., Soma A., Veres I., Juhasz I., Brown E.J., Capobianco A.J., Herlyn M., Liu Z.J. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J.Clin. Invest. 2005, 115:3166-3176.
14. Bedogni B., Warneke J.A., Nickoloff B.J., Giaccia A.J., Powell M.B. Notch1 is an effector of Akt and hypoxia in melanoma development. J.Clin. Invest. 2008, 118:3660-3670.
15. Benedito R., Roca C., Sörensen I., Adams S., Gossler A., Fruttiger M., Adams R.H. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009, 137:1124-1135.
16. Blaumueller C.M., Qi H., Zagouras P., Artavanis-Tsakonas S. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell 1997, 90:281-291.
17. Brabletz S., Bajdak K., Meidhof S., Burk U., Niedermann G., Firat E., Wellner U., Dimmler A., Faller G., Schubert J., Brabletz T. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J. 2011, 30:770-782.
18. Bray S.J. Notch signalling: a simple pathway becomes complex. Nat. Rev. Mol. Cell Biol. 2006, 7:678-689.
19. Breit S., Stanulla M., Flohr T., Schrappe M., Ludwig W.D., Tolle G., Happich M., Muckenthaler M.U., Kulozik A.E. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006, 108:1151-1157.
20. Bu P., Chen K.Y., Chen J.H., Wang L., Walters J., Shin Y.J., Goerger J.P., Sun J., Witherspoon M., Rakhilin N., et al. A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. Cell Stem Cell 2013, 12:602-615.
21. Camargo F.D., Gokhale S., Johnnidis J.B., Fu D., Bell G.W., Jaenisch R., Brummelkamp T.R. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr. Biol. 2007, 17:2054-2060.
22. Camps J., Pitt J.J., Emons G., Hummon A.B., Case C.M., Grade M., Jones T.L., Nguyen Q.T., Ghadimi B.M., Beissbarth T., et al. Genetic amplification of the NOTCH modulator LNX2 upregulates the WNT/β-catenin pathway in colorectal cancer. Cancer Res. 2013, 73:2003-2013.
23. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
24. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525. Cancer Genome Atlas Research Network.
25. Capobianco A.J., Zagouras P., Blaumueller C.M., Artavanis-Tsakonas S., Bishop J.M. Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2. Mol. Cell. Biol. 1997, 17:6265-6273.
26. Castel D., Mourikis P., Bartels S.J., Brinkman A.B., Tajbakhsh S., Stunnenberg H.G. Dynamic binding of RBPJ is determined by Notch signaling status. Genes Dev. 2013, 27:1059-1071.
27. Chen P.M., Yen C.C., Wang W.S., Lin Y.J., Chu C.J., Chiou T.J., Liu J.H., Yang M.H. Down-regulation of Notch-1 expression decreases PU.1-mediated myeloid differentiation signaling in acute myeloid leukemia. Int. J. Oncol. 2008, 32:1335-1341.
28. Chu Q., Orr B.A., Semenkow S., Bar E.E., Eberhart C.G. ). Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following invivo Notch blockade. Clin. Cancer Res. 2013, 19:3224-3233.
29. Clappier E., Collette S., Grardel N., Girard S., Suarez L., Brunie G., Kaltenbach S., Yakouben K., Mazingue F., Robert A., et al. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia 2010, 24:2023-2031. EORTC-CLG.
30. Colaluca I.N., Tosoni D., Nuciforo P., Senic-Matuglia F., Galimberti V., Viale G., Pece S., Di Fiore P.P. NUMB controls p53 tumour suppressor activity. Nature 2008, 451:76-80.
31. Cook M., Yu X.M., Chen H. Notch in the development of thyroid C-cells and the treatment of medullary thyroid cancer. Am. J. Transl. Res. 2010, 2:119-125.
32. Cook N., Frese K.K., Bapiro T.E., Jacobetz M.A., Gopinathan A., Miller J.L., Rao S.S., Demuth T., Howat W.J., Jodrell D.I., Tuveson D.A. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J.Exp. Med. 2012, 209:437-444.
33. Croquelois A., Blindenbacher A., Terracciano L., Wang X., Langer I., Radtke F., Heim M.H. Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice. Hepatology 2005, 41:487-496.
34. Cui H., Kong Y., Xu M., Zhang H. Notch3 functions as a tumor suppressor by controlling cellular senescence. Cancer Res. 2013, 73:3451-3459.
35. Dan H.C., Cooper M.J., Cogswell P.C., Duncan J.A., Ting J.P., Baldwin A.S. Akt-dependent regulation of NF-kappaB is controlled by mTOR and Raptor in association with IKK. Genes Dev. 2008, 22:1490-1500.
36. Dang T.P., Eichenberger S., Gonzalez A., Olson S., Carbone D.P. Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice. Oncogene 2003, 22:1988-1997.
37. De La O J.P., Emerson L.L., Goodman J.L., Froebe S.C., Illum B.E., Curtis A.B., Murtaugh L.C. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc. Natl. Acad. Sci. USA 2008, 105:18907-18912.
38. De Strooper B., Annaert W., Cupers P., Saftig P., Craessaerts K., Mumm J.S., Schroeter E.H., Schrijvers V., Wolfe M.S., Ray W.J., et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999, 398:518-522.
39. Dexter J.S. The analysis of a case of continuous variation in Drosophila by a study of its linkage relationships. Am. Nat. 1914, 48:712-758.
40. Dill M.T., Tornillo L., Fritzius T., Terracciano L., Semela D., Bettler B., Heim M.H., Tchorz J.S. Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology 2013, 57:1607-1619.
41. Eliasz S., Liang S., Chen Y., De Marco M.A., Machek O., Skucha S., Miele L., Bocchetta M. Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene 2010, 29:2488-2498.
42. Ellisen L.W., Bird J., West D.C., Soreng A.L., Reynolds T.C., Smith S.D., Sklar J. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991, 66:649-661.
43. Espinosa L., Cathelin S., D'Altri T., Trimarchi T., Statnikov A., Guiu J., Rodilla V., Inglés-Esteve J., Nomdedeu J., Bellosillo B., et al. The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in Tcell leukemia. Cancer Cell 2010, 18:268-281.
44. Fabbri G., Rasi S., Rossi D., Trifonov V., Khiabanian H., Ma J., Grunn A., Fangazio M., Capello D., Monti S., et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J.Exp. Med. 2011, 208:1389-1401.
45. Fan X., Mikolaenko I., Elhassan I., Ni X., Wang Y., Ball D., Brat D.J., Perry A., Eberhart C.G. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res. 2004, 64:7787-7793.
46. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H.F., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
47. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
48. Fischer M., Yen W.C., Kapoun A.M., Wang M., O'Young G., Lewicki J., Gurney A., Hoey T. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res. 2011, 71:1520-1525.
49. Fitzgerald K., Harrington A., Leder P. Ras pathway signals are required for notch-mediated oncogenesis. Oncogene 2000, 19:4191-4198.
50. Fortini M.E., Rebay I., Caron L.A., Artavanis-Tsakonas S. An activated Notch receptor blocks cell-fate commitment in the developing Drosophila eye. Nature 1993, 365:555-557.
51. Fre S., Huyghe M., Mourikis P., Robine S., Louvard D., Artavanis-Tsakonas S. Notch signals control the fate of immature progenitor cells in the intestine. Nature 2005, 435:964-968.
52. Fre S., Pallavi S.K., Huyghe M., Laé M., Janssen K.P., Robine S., Artavanis-Tsakonas S., Louvard D. Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. Proc. Natl. Acad. Sci. USA 2009, 106:6309-6314.
53. Fre S., Hannezo E., Sale S., Huyghe M., Lafkas D., Kissel H., Louvi A., Greve J., Louvard D., Artavanis-Tsakonas S. Notch lineages and activity in intestinal stem cells determined by a new set of knock-in mice. PLoS ONE 2011, 6:e25785.
54. Fryer C.J., White J.B., Jones K.A. Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol. Cell 2004, 16:509-520.
55. Fu Y.P., Edvardsen H., Kaushiva A., Arhancet J.P., Howe T.M., Kohaar I., Porter-Gill P., Shah A., Landmark-Høyvik H., Fosså S.D., et al. NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations. Mol. Cancer 2010, 9:113.
56. Fujimoto A., Totoki Y., Abe T., Boroevich K.A., Hosoda F., Nguyen H.H., Aoki M., Hosono N., Kubo M., Miya F., et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 2012, 44:760-764.
57. Funahashi Y., Hernandez S.L., Das I., Ahn A., Huang J., Vorontchikhina M., Sharma A., Kanamaru E., Borisenko V., Desilva D.M., et al. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res. 2008, 68:4727-4735.
58. Gallahan D., Callahan R. The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4). Oncogene 1997, 14:1883-1890.
59. Gallahan D., Kozak C., Callahan R. A new common integration region (int-3) for mouse mammary tumor virus on mouse chromosome 17. J.Virol. 1987, 61:218-220.
60. Giancotti F.G. Mechanisms governing metastatic dormancy and reactivation. Cell 2013, 155:750-764.
61. Girard L., Hanna Z., Beaulieu N., Hoemann C.D., Simard C., Kozak C.A., Jolicoeur P. Frequent provirus insertional mutagenesis of Notch1 in thymomas of MMTVD/myc transgenic mice suggests a collaboration of c-myc and Notch1 for oncogenesis. Genes Dev. 1996, 10:1930-1944.
62. Gross S., Cairns R.A., Minden M.D., Driggers E.M., Bittinger M.A., Jang H.G., Sasaki M., Jin S., Schenkein D.P., Su S.M., et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J.Exp. Med. 2010, 207:339-344.
63. Guest R.V., Boulter L., Kendall T.J., Minnis-Lyons S.E., Walker R., Wigmore S.J., Sansom O.J., Forbes S.J. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. Cancer Res. 2014, 74:1005-1010.
64. Guichard C., Amaddeo G., Imbeaud S., Ladeiro Y., Pelletier L., Maad I.B., Calderaro J., Bioulac-Sage P., Letexier M., Degos F., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 2012, 44:694-698.
65. Haines N., Irvine K.D. Glycosylation regulates Notch signalling. Nat. Rev. Mol. Cell Biol. 2003, 4:786-797.
66. Hanlon L., Avila J.L., Demarest R.M., Troutman S., Allen M., Ratti F., Rustgi A.K., Stanger B.Z., Radtke F., Adsay V., et al. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res. 2010, 70:4280-4286.
67. Hansson E.M., Teixeira A.I., Gustafsson M.V., Dohda T., Chapman G., Meletis K., Muhr J., Lendahl U. Recording Notch signaling in real time. Dev. Neurosci. 2006, 28:118-127.
68. Harrison H., Farnie G., Howell S.J., Rock R.E., Stylianou S., Brennan K.R., Bundred N.J., Clarke R.B. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010, 70:709-718.
69. Haruki N., Kawaguchi K.S., Eichenberger S., Massion P.P., Olson S., Gonzalez A., Carbone D.P., Dang T.P. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Res. 2005, 65:3555-3561.
70. Hassan K.A., Wang L., Korkaya H., Chen G., Maillard I., Beer D.G., Kalemkerian G.P., Wicha M.S. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin. Cancer Res. 2013, 19:1972-1980.
71. Hicks C., Ladi E., Lindsell C., Hsieh J.J., Hayward S.D., Collazo A., Weinmaster G. A secreted Delta1-Fc fusion protein functions both as an activator and inhibitor of Notch1 signaling. J.Neurosci. Res. 2002, 68:655-667.
72. Hodis E., Watson I.R., Kryukov G.V., Arold S.T., Imielinski M., Theurillat J.P., Nickerson E., Auclair D., Li L., Place C., et al. A landscape of driver mutations in melanoma. Cell 2012, 150:251-263.
73. Hoey T., Yen W.C., Axelrod F., Basi J., Donigian L., Dylla S., Fitch-Bruhns M., Lazetic S., Park I.K., Sato A., et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009, 5:168-177.
74. Huynh C., Poliseno L., Segura M.F., Medicherla R., Haimovic A., Menendez S., Shang S., Pavlick A., Shao Y., Darvishian F., et al. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PLoS ONE 2011, 6:e25264.
75. Ilagan M.X., Kopan R. Selective blockade of transport via SERCA inhibition: the answer for oncogenic forms of Notch?. Cancer Cell 2013, 23:267-269.
76. Imatani A., Callahan R. Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines. Oncogene 2000, 19:223-231.
77. Iso T., Sartorelli V., Chung G., Shichinohe T., Kedes L., Hamamori Y. HERP, a new primary target of Notch regulated by ligand binding. Mol. Cell. Biol. 2001, 21:6071-6079.
78. Iso T., Sartorelli V., Poizat C., Iezzi S., Wu H.Y., Chung G., Kedes L., Hamamori Y. HERP, a novel heterodimer partner of HES/E(spl) in Notch signaling. Mol. Cell. Biol. 2001, 21:6080-6089.
79. Izrailit J., Berman H.K., Datti A., Wrana J.L., Reedijk M. High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGFβ pathways as fundamental Notch regulators in breast cancer. Proc. Natl. Acad. Sci. USA 2013, 110:1714-1719.
80. Jarriault S., Brou C., Logeat F., Schroeter E.H., Kopan R., Israel A. Signalling downstream of activated mammalian Notch. Nature 1995, 377:355-358.
81. Jeliazkova P., Jörs S., Lee M., Zimber-Strobl U., Ferrer J., Schmid R.M., Siveke J.T., Geisler F. Canonical Notch2 signaling determines biliary cell fates of embryonic hepatoblasts and adult hepatocytes independent of Hes1. Hepatology 2013, 57:2469-2479.
82. Jhappan C., Gallahan D., Stahle C., Chu E., Smith G.H., Merlino G., Callahan R. Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev. 1992, 6:345-355.
83. Joshi I., Minter L.M., Telfer J., Demarest R.M., Capobianco A.J., Aster J.C., Sicinski P., Fauq A., Golde T.E., Osborne B.A. Notch signaling mediates G1/S cell-cycle progression in Tcells via cyclin D3 and its dependent kinases. Blood 2009, 113:1689-1698.
84. Jundt F., Acikgöz O., Kwon S.H., Schwarzer R., Anagnostopoulos I., Wiesner B., Mathas S., Hummel M., Stein H., Reichardt H.M., Dörken B. Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. Leukemia 2008, 22:1587-1594.
85. Kannan S., Sutphin R.M., Hall M.G., Golfman L.S., Fang W., Nolo R.M., Akers L.J., Hammitt R.A., McMurray J.S., Kornblau S.M., et al. Notch activation inhibits AML growth and survival: a potential therapeutic approach. J.Exp. Med. 2013, 210:321-337.
86. Kidd S., Kelley M.R., Young M.W. Sequence of the notch locus of Drosophila melanogaster: relationship of the encoded protein to mammalian clotting and growth factors. Mol. Cell. Biol. 1986, 6:3094-3108.
87. Kiel M.J., Velusamy T., Betz B.L., Zhao L., Weigelin H.G., Chiang M.Y., Huebner-Chan D.R., Bailey N.G., Yang D.T., Bhagat G., et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J.Exp. Med. 2012, 209:1553-1565.
88. Kim H.A., Koo B.K., Cho J.H., Kim Y.Y., Seong J., Chang H.J., Oh Y.M., Stange D.E., Park J.G., Hwang D., Kong Y.Y. Notch1 counteracts WNT/β-catenin signaling through chromatin modification in colorectal cancer. J.Clin. Invest. 2012, 122:3248-3259.
89. King B., Trimarchi T., Reavie L., Xu L., Mullenders J., Ntziachristos P., Aranda-Orgilles B., Perez-Garcia A., Shi J., Vakoc C., et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 2013, 153:1552-1566.
90. Klinakis A., Lobry C., Abdel-Wahab O., Oh P., Haeno H., Buonamici S., van De Walle I., Cathelin S., Trimarchi T., Araldi E., et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 2011, 473:230-233.
91. Kluk M.J., Ashworth T., Wang H., Knoechel B., Mason E.F., Morgan E.A., Dorfman D., Pinkus G., Weigert O., Hornick J.L., et al. Gauging NOTCH1 activation in cancer using immunohistochemistry. PLoS ONE 2013, 8:e67306.
92. Krämer A., Mentrup T., Kleizen B., Rivera-Milla E., Reichenbach D., Enzensperger C., Nohl R., Täuscher E., Görls H., Ploubidou A., et al. Small molecules intercept Notch signaling and the early secretory pathway. Nat. Chem. Biol. 2013, 9:731-738.
93. Kuang S.Q., Fang Z., Zweidler-McKay P.A., Yang H., Wei Y., Gonzalez-Cervantes E.A., Boumber Y., Garcia-Manero G. Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia. PLoS ONE 2013, 8:e61807.
94. Kwon C., Cheng P., King I.N., Andersen P., Shenje L., Nigam V., Srivastava D. Notch post-translationally regulates β-catenin protein in stem and progenitor cells. Nat. Cell Biol. 2011, 13:1244-1251.
95. LaVoie M.J., Selkoe D.J. The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J.Biol. Chem. 2003, 278:34427-34437.
96. Lee S.Y., Kumano K., Nakazaki K., Sanada M., Matsumoto A., Yamamoto G., Nannya Y., Suzuki R., Ota S., Ota Y., et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci. 2009, 100:920-926.
97. Lei L., Xu A., Panin V.M., Irvine K.D. An O-fucose site in the ligand binding domain inhibits Notch activation. Development 2003, 130:6411-6421.
98. Lewis H.D., Leveridge M., Strack P.R., Haldon C.D., O'Neil J., Kim H., Madin A., Hannam J.C., Look A.T., Kohl N., et al. Apoptosis in Tcell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem. Biol. 2007, 14:209-219.
99. Li J.L., Harris A.L. Notch signaling from tumor cells: a new mechanism of angiogenesis. Cancer Cell 2005, 8:1-3.
100. Li X., von Boehmer H. Notch Signaling in T-Cell Development and T-ALL. ISRN Hematol. 2011, 2011:921706.
101. Licciulli S., Avila J.L., Hanlon L., Troutman S., Cesaroni M., Kota S., Keith B., Simon M.C., Puré E., Radtke F., et al. Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53. Cancer Res. 2013, 73:5974-5984.
102. Lim S.O., Kim H.S., Quan X., Ahn S.M., Kim H., Hsieh D., Seong J.K., Jung G. Notch1 binds and induces degradation of Snail in hepatocellular carcinoma. BMC Biol. 2011, 9:83.
103. Liu Z., Turkoz A., Jackson E.N., Corbo J.C., Engelbach J.A., Garbow J.R., Piwnica-Worms D.R., Kopan R. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J.Clin. Invest. 2011, 121:800-808.
104. Lobov I.B., Cheung E., Wudali R., Cao J., Halasz G., Wei Y., Economides A., Lin H.C., Papadopoulos N., Yancopoulos G.D., Wiegand S.J. The Dll4/Notch pathway controls postangiogenic blood vessel remodeling and regression by modulating vasoconstriction and blood flow. Blood 2011, 117:6728-6737.
105. Lobry C., Ntziachristos P., Ndiaye-Lobry D., Oh P., Cimmino L., Zhu N., Araldi E., Hu W., Freund J., Abdel-Wahab O., et al. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J.Exp. Med. 2013, 210:301-319.
106. Love C., Sun Z., Jima D., Li G., Zhang J., Miles R., Richards K.L., Dunphy C.H., Choi W.W., Srivastava G., et al. The genetic landscape of mutations in Burkitt lymphoma. Nat. Genet. 2012, 44:1321-1325.
107. Lu J., Ye X., Fan F., Xia L., Bhattacharya R., Bellister S., Tozzi F., Sceusi E., Zhou Y., Tachibana I., et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 2013, 23:171-185.
108. Maliekal T.T., Bajaj J., Giri V., Subramanyam D., Krishna S. The role of Notch signaling in human cervical cancer: implications for solid tumors. Oncogene 2008, 27:5110-5114.
109. Malyukova A., Dohda T., von der Lehr N., Akhoondi S., Corcoran M., Heyman M., Spruck C., Grandér D., Lendahl U., Sangfelt O. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res. 2007, 67:5611-5616.
110. Maraver A., Fernandez-Marcos P.J., Herranz D., Cañamero M., Muñoz-Martin M., Gómez-López G., Mulero F., Megías D., Sanchez-Carbayo M., Shen J., et al. Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell 2012, 22:222-234.
111. Marignol L., Rivera-Figueroa K., Lynch T., Hollywood D. Hypoxia, notch signalling, and prostate cancer. Nat. Rev. Urol. 2013, 10:405-413.
112. Mazur P.K., Einwächter H., Lee M., Sipos B., Nakhai H., Rad R., Zimber-Strobl U., Strobl L.J., Radtke F., Klöppel G., et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc. Natl. Acad. Sci. USA 2010, 107:13438-13443.
113. Mazzone M., Selfors L.M., Albeck J., Overholtzer M., Sale S., Carroll D.L., Pandya D., Lu Y., Mills G.B., Aster J.C., et al. Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc. Natl. Acad. Sci. USA 2010, 107:5012-5017.
114. McAuliffe S.M., Morgan S.L., Wyant G.A., Tran L.T., Muto K.W., Chen Y.S., Chin K.T., Partridge J.C., Poole B.B., Cheng K.H., et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc. Natl. Acad. Sci. USA 2012, 109:E2939-E2948.
115. McCaffrey L.M., Montalbano J., Mihai C., Macara I.G. Loss of the Par3 polarity protein promotes breast tumorigenesis and metastasis. Cancer Cell 2012, 22:601-614.
116. McDaniell R., Warthen D.M., Sanchez-Lara P.A., Pai A., Krantz I.D., Piccoli D.A., Spinner N.B. NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am. J. Hum. Genet. 2006, 79:169-173.
117. Meurette O., Stylianou S., Rock R., Collu G.M., Gilmore A.P., Brennan K. Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Res. 2009, 69:5015-5022.
118. Miyaki M., Yamaguchi T., Iijima T., Takahashi K., Matsumoto H., Mori T. Somatic mutations of the CDC4 (FBXW7) gene in hereditary colorectal tumors. Oncology 2009, 76:430-434.
119. Miyamoto Y., Maitra A., Ghosh B., Zechner U., Argani P., Iacobuzio-Donahue C.A., Sriuranpong V., Iso T., Meszoely I.M., Wolfe M.S., et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003, 3:565-576.
120. Mizuma M., Rasheed Z.A., Yabuuchi S., Omura N., Campbell N.R., de Wilde R.F., De Oliveira E., Zhang Q., Puig O., Matsui W., et al. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Mol. Cancer Ther. 2012, 11:1999-2009.
121. Mizutani K., Yoon K., Dang L., Tokunaga A., Gaiano N. Differential Notch signalling distinguishes neural stem cells from intermediate progenitors. Nature 2007, 449:351-355.
122. Moellering R.E., Cornejo M., Davis T.N., Del Bianco C., Aster J.C., Blacklow S.C., Kung A.L., Gilliland D.G., Verdine G.L., Bradner J.E. Direct inhibition of the NOTCH transcription factor complex. Nature 2009, 462:182-188.
123. Morgan T. The theory of the gene. Am. Nat. 1917, 51:513-544.
124. Morin R.D., Mendez-Lago M., Mungall A.J., Goya R., Mungall K.L., Corbett R.D., Johnson N.A., Severson T.M., Chiu R., Field M., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476:298-303.
125. Mukherjee A., Veraksa A., Bauer A., Rosse C., Camonis J., Artavanis-Tsakonas S. Regulation of Notch signalling by non-visual beta-arrestin. Nat. Cell Biol. 2005, 7:1191-1201.
126. Mullendore M.E., Koorstra J.B., Li Y.M., Offerhaus G.J., Fan X., Henderson C.M., Matsui W., Eberhart C.G., Maitra A., Feldmann G. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin. Cancer Res. 2009, 15:2291-2301.
127. Nam Y., Sliz P., Song L., Aster J.C., Blacklow S.C. Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell 2006, 124:973-983.
128. Nicolas M., Wolfer A., Raj K., Kummer J.A., Mill P., van Noort M., Hui C.C., Clevers H., Dotto G.P., Radtke F. Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 2003, 33:416-421.
129. Noguera-Troise I., Daly C., Papadopoulos N.J., Coetzee S., Boland P., Gale N.W., Lin H.C., Yancopoulos G.D., Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006, 444:1032-1037.
130. Nowell C., Radtke F. Cutaneous notch signaling in health and disease. Cold Spring Harb. Perspect. Med. 2013, 3:a017772.
131. Ntziachristos P., Tsirigos A., Van Vlierberghe P., Nedjic J., Trimarchi T., Flaherty M.S., Ferres-Marco D., da Ros V., Tang Z., Siegle J., et al. Genetic inactivation of the polycomb repressive complex 2 in Tcell acute lymphoblastic leukemia. Nat. Med. 2012, 18:298-301.
132. O'Neil J., Grim J., Strack P., Rao S., Tibbitts D., Winter C., Hardwick J., Welcker M., Meijerink J.P., Pieters R., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J.Exp. Med. 2007, 204:1813-1824.
133. Oda T., Elkahloun A.G., Pike B.L., Okajima K., Krantz I.D., Genin A., Piccoli D.A., Meltzer P.S., Spinner N.B., Collins F.S., Chandrasekharappa S.C. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat. Genet. 1997, 16:235-242.
134. Oh P., Lobry C., Gao J., Tikhonova A., Loizou E., Manent J., van Handel B., Ibrahim S., Greve J., Mikkola H., et al. Invivo mapping of notch pathway activity in normal and stress hematopoiesis. Cell Stem Cell 2013, 13:190-204.
135. Okajima T., Irvine K.D. Regulation of notch signaling by o-linked fucose. Cell 2002, 111:893-904.
136. Okajima T., Xu A., Irvine K.D. Modulation of notch-ligand binding by protein O-fucosyltransferase 1 and fringe. J.Biol. Chem. 2003, 278:42340-42345.
137. Ortica S., Tarantino N., Aulner N., Israel A., Gupta-Rossi N. The 4 Notch receptors play distinct and antagonistic roles in the proliferation and hepatocytic differentiation of liver progenitors. FASEB J. 2014, 28:603-614.
138. Oscier D.G., Rose-Zerilli M.J., Winkelmann N., Gonzalez de Castro D., Gomez B., Forster J., Parker H., Parker A., Gardiner A., Collins A., et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013, 121:468-475.
139. Oskarsson T., Acharyya S., Zhang X.H., Vanharanta S., Tavazoie S.F., Morris P.G., Downey R.J., Manova-Todorova K., Brogi E., Massagué J. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat. Med. 2011, 17:867-874.
140. Palomero T., Ferrando A. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. Clin. Lymphoma Myeloma 2009, 9(Suppl 3):S205-S210.
141. Palomero T., Lim W.K., Odom D.T., Sulis M.L., Real P.J., Margolin A., Barnes K.C., O'Neil J., Neuberg D., Weng A.P., et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl. Acad. Sci. USA 2006, 103:18261-18266.
142. Park M.J., Taki T., Oda M., Watanabe T., Yumura-Yagi K., Kobayashi R., Suzuki N., Hara J., Horibe K., Hayashi Y. FBXW7 and NOTCH1 mutations in childhood Tcell acute lymphoblastic leukaemia and Tcell non-Hodgkin lymphoma. Br. J. Haematol. 2009, 145:198-206.
143. Pasqualucci L., Khiabanian H., Fangazio M., Vasishtha M., Messina M., Holmes A.B., Ouillette P., Trifonov V., Rossi D., Tabbo F., et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014, 6:130-140.
144. Pear W.S., Aster J.C., Scott M.L., Hasserjian R.P., Soffer B., Sklar J., Baltimore D. Exclusive development of Tcell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J.Exp. Med. 1996, 183:2283-2291.
145. Pece S., Serresi M., Santolini E., Capra M., Hulleman E., Galimberti V., Zurrida S., Maisonneuve P., Viale G., Di Fiore P.P. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J.Cell Biol. 2004, 167:215-221.
146. Peifer M., Fernández-Cuesta L., Sos M.L., George J., Seidel D., Kasper L.H., Plenker D., Leenders F., Sun R., Zander T., et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 2012, 44:1104-1110.
147. Peignon G., Durand A., Cacheux W., Ayrault O., Terris B., Laurent-Puig P., Shroyer N.F., Van Seuningen I., Honjo T., Perret C., Romagnolo B. Complex interplay between β-catenin signalling and Notch effectors in intestinal tumorigenesis. Gut 2011, 60:166-176.
148. Phng L.K., Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev. Cell 2009, 16:196-208.
149. Pickering C.R., Zhang J., Yoo S.Y., Bengtsson L., Moorthy S., Neskey D.M., Zhao M., Ortega Alves M.V., Chang K., Drummond J., et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 2013, 3:770-781.
150. Plentz R., Park J.S., Rhim A.D., Abravanel D., Hezel A.F., Sharma S.V., Gurumurthy S., Deshpande V., Kenific C., Settleman J., et al. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2009, 136:1741-1749.
151. Proweller A., Tu L., Lepore J.J., Cheng L., Lu M.M., Seykora J., Millar S.E., Pear W.S., Parmacek M.S. Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res. 2006, 66:7438-7444.
152. Puente X.S., Pinyol M., Quesada V., Conde L., Ordóñez G.R., Villamor N., Escaramis G., Jares P., Beà S., González-Díaz M., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105.
153. Pui J.C., Allman D., Xu L., DeRocco S., Karnell F.G., Bakkour S., Lee J.Y., Kadesch T., Hardy R.R., Aster J.C., Pear W.S. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 1999, 11:299-308.
154. Purow B. Notch inhibition as a promising new approach to cancer therapy. Adv. Exp. Med. Biol. 2012, 727:305-319.
155. Qi R., An H., Yu Y., Zhang M., Liu S., Xu H., Guo Z., Cheng T., Cao X. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res. 2003, 63:8323-8329.
156. Radtke F., Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 2005, 307:1904-1909.
157. Radtke F., Wilson A., Stark G., Bauer M., van Meerwijk J., MacDonald H.R., Aguet M. Deficient Tcell fate specification in mice with an induced inactivation of Notch1. Immunity 1999, 10:547-558.
158. Radtke F., MacDonald H.R., Tacchini-Cottier F. Regulation of innate and adaptive immunity by Notch. Nat. Rev. Immunol. 2013, 13:427-437.
159. Ranganathan P., Weaver K.L., Capobianco A.J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer 2011, 11:338-351.
160. Rangarajan A., Talora C., Okuyama R., Nicolas M., Mammucari C., Oh H., Aster J.C., Krishna S., Metzger D., Chambon P., et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 2001, 20:3427-3436.
161. Real P.J., Tosello V., Palomero T., Castillo M., Hernando E., de Stanchina E., Sulis M.L., Barnes K., Sawai C., Homminga I., et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in Tcell acute lymphoblastic leukemia. Nat. Med. 2009, 15:50-58.
162. Rebay I., Fleming R.J., Fehon R.G., Cherbas L., Cherbas P., Artavanis-Tsakonas S. Specific EGF repeats of Notch mediate interactions with Delta and Serrate: implications for Notch as a multifunctional receptor. Cell 1991, 67:687-699.
163. Ridgway J., Zhang G., Wu Y., Stawicki S., Liang W.C., Chanthery Y., Kowalski J., Watts R.J., Callahan C., Kasman I., et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006, 444:1083-1087.
164. Robbins J., Blondel B.J., Gallahan D., Callahan R. Mouse mammary tumor gene int-3: a member of the notch gene family transforms mammary epithelial cells. J.Virol. 1992, 66:2594-2599.
165. Robinson D.R., Kalyana-Sundaram S., Wu Y.M., Shankar S., Cao X., Ateeq B., Asangani I.A., Iyer M., Maher C.A., Grasso C.S., et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat. Med. 2011, 17:1646-1651.
166. Rodilla V., Villanueva A., Obrador-Hevia A., Robert-Moreno A., Fernández-Majada V., Grilli A., López-Bigas N., Bellora N., Albà M.M., Torres F., et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc. Natl. Acad. Sci. USA 2009, 106:6315-6320.
167. Rossi D., Rasi S., Fabbri G., Spina V., Fangazio M., Forconi F., Marasca R., Laurenti L., Bruscaggin A., Cerri M., et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012, 119:521-529.
168. Rossi D., Trifonov V., Fangazio M., Bruscaggin A., Rasi S., Spina V., Monti S., Vaisitti T., Arruga F., Famà R., et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J.Exp. Med. 2012, 209:1537-1551.
169. Rothenberg S.M., Ellisen L.W. The molecular pathogenesis of head and neck squamous cell carcinoma. J.Clin. Invest. 2012, 122:1951-1957.
170. Roulland S., Faroudi M., Mamessier E., Sungalee S., Salles G., Nadel B. Early steps of follicular lymphoma pathogenesis. Adv. Immunol. 2011, 111:1-46.
171. Rudin C.M., Durinck S., Stawiski E.W., Poirier J.T., Modrusan Z., Shames D.S., Bergbower E.A., Guan Y., Shin J., Guillory J., et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 2012, 44:1111-1116.
172. Sahlgren C., Gustafsson M.V., Jin S., Poellinger L., Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc. Natl. Acad. Sci. USA 2008, 105:6392-6397.
173. Salcido C.D., Larochelle A., Taylor B.J., Dunbar C.E., Varticovski L. Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br. J. Cancer 2010, 102:1636-1644.
174. Šale S., Lafkas D., Artavanis-Tsakonas S. Notch2 genetic fate mapping reveals two previously unrecognized mammary epithelial lineages. Nat. Cell Biol. 2013, 15:451-460.
175. Sancho R., Jandke A., Davis H., Diefenbacher M.E., Tomlinson I., Behrens A. F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor. Gastroenterology 2010, 139:929-941.
176. Santagata S., Demichelis F., Riva A., Varambally S., Hofer M.D., Kutok J.L., Kim R., Tang J., Montie J.E., Chinnaiyan A.M., et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 2004, 64:6854-6857.
177. Sasaki M., Knobbe C.B., Munger J.C., Lind E.F., Brenner D., Brüstle A., Harris I.S., Holmes R., Wakeham A., Haight J., et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012, 488:656-659.
178. Sawai C.M., Freund J., Oh P., Ndiaye-Lobry D., Bretz J.C., Strikoudis A., Genesca L., Trimarchi T., Kelliher M.A., Clark M., et al. Therapeutic targeting of the cyclin D3:CDK4/6 complex in Tcell leukemia. Cancer Cell 2012, 22:452-465.
179. Schroeter E.H., Kisslinger J.A., Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 1998, 393:382-386.
180. Schwarzer R., Jundt F. Notch and NF-κB signaling pathways in the biology of classical Hodgkin lymphoma. Curr. Mol. Med. 2011, 11:236-245.
181. Schwarzer R., Dörken B., Jundt F. Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells. Leukemia 2012, 26:806-813.
182. Sethi N., Dai X., Winter C.G., Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011, 19:192-205.
183. Shah S., Lee S.F., Tabuchi K., Hao Y.H., Yu C., LaPlant Q., Ball H., Dann C.E., Südhof T., Yu G. Nicastrin functions as a gamma-secretase-substrate receptor. Cell 2005, 122:435-447.
184. Sharma V.M., Calvo J.A., Draheim K.M., Cunningham L.A., Hermance N., Beverly L., Krishnamoorthy V., Bhasin M., Capobianco A.J., Kelliher M.A. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol. Cell. Biol. 2006, 26:8022-8031.
185. Six E., Ndiaye D., Laabi Y., Brou C., Gupta-Rossi N., Israel A., Logeat F. The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and gamma-secretase. Proc. Natl. Acad. Sci. USA 2003, 100:7638-7643.
186. Sjölund J., Johansson M., Manna S., Norin C., Pietras A., Beckman S., Nilsson E., Ljungberg B., Axelson H. Suppression of renal cell carcinoma growth by inhibition of Notch signaling invitro and invivo. J.Clin. Invest. 2008, 118:217-228.
187. Sonoshita M., Aoki M., Fuwa H., Aoki K., Hosogi H., Sakai Y., Hashida H., Takabayashi A., Sasaki M., Robine S., et al. Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell 2011, 19:125-137.
188. Souilhol C., Cormier S., Monet M., Vandormael-Pournin S., Joutel A., Babinet C., Cohen-Tannoudji M. Nas transgenic mouse line allows visualization of Notch pathway activity invivo. Genesis 2006, 44:277-286.
189. South A.P., Cho R.J., Aster J.C. The double-edged sword of Notch signaling in cancer. Semin. Cell Dev. Biol. 2012, 23:458-464.
190. Sriuranpong V., Borges M.W., Ravi R.K., Arnold D.R., Nelkin B.D., Baylin S.B., Ball D.W. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res. 2001, 61:3200-3205.
191. Sriuranpong V., Borges M.W., Strock C.L., Nakakura E.K., Watkins D.N., Blaumueller C.M., Nelkin B.D., Ball D.W. Notch signaling induces rapid degradation of achaete-scute homolog 1. Mol. Cell. Biol. 2002, 22:3129-3139.
192. Stockhausen M.T., Sjölund J., Manetopoulos C., Axelson H. Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. Br. J. Cancer 2005, 92:751-759.
193. Sulis M.L., Williams O., Palomero T., Tosello V., Pallikuppam S., Real P.J., Barnes K., Zuurbier L., Meijerink J.P., Ferrando A.A. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood 2008, 112:733-740.
194. Sun W., Gaykalova D.A., Ochs M.F., Mambo E., Arnaoutakis D., Liu Y., Loyo M., Agrawal N., Howard J., Li R., et al. Activation of the NOTCH pathway in head and neck cancer. Cancer Res. 2014, 74:1091-1104.
195. Thompson B.J., Buonamici S., Sulis M.L., Palomero T., Vilimas T., Basso G., Ferrando A., Aifantis I. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in Tcell leukemia. J.Exp. Med. 2007, 204:1825-1835.
196. Thurber A.E., Douglas G., Sturm E.C., Zabierowski S.E., Smit D.J., Ramakrishnan S.N., Hacker E., Leonard J.H., Herlyn M., Sturm R.A. Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene 2011, 30:3036-3048.
197. Timmerman L.A., Grego-Bessa J., Raya A., Bertrán E., Pérez-Pomares J.M., Díez J., Aranda S., Palomo S., McCormick F., Izpisúa-Belmonte J.C., de la Pompa J.L. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004, 18:99-115.
198. Tschaharganeh D.F., Chen X., Latzko P., Malz M., Gaida M.M., Felix K., Ladu S., Singer S., Pinna F., Gretz N., et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology 2013, 144:1530-1542.
199. van Es J.H., van Gijn M.E., Riccio O., van den Born M., Vooijs M., Begthel H., Cozijnsen M., Robine S., Winton D.J., Radtke F., Clevers H. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 435:959-963.
200. Viatour P., Ehmer U., Saddic L.A., Dorrell C., Andersen J.B., Lin C., Zmoos A.F., Mazur P.K., Schaffer B.E., Ostermeier A., et al. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J.Exp. Med. 2011, 208:1963-1976.
201. Vilimas T., Mascarenhas J., Palomero T., Mandal M., Buonamici S., Meng F., Thompson B., Spaulding C., Macaroun S., Alegre M.L., et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat. Med. 2007, 13:70-77.
202. Villanueva A., Alsinet C., Yanger K., Hoshida Y., Zong Y., Toffanin S., Rodriguez-Carunchio L., Sole M., Thung S., Stanger B.Z., Llovet J.M. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 2012, 143:1660-1669.
203. Wang M., Xue L., Cao Q., Lin Y., Ding Y., Yang P., Che L. Expression of Notch1, Jagged1 and beta-catenin and their clinicopathological significance in hepatocellular carcinoma. Neoplasma 2009, 56:533-541.
204. Wang J., Wakeman T.P., Lathia J.D., Hjelmeland A.B., Wang X.F., White R.R., Rich J.N., Sullenger B.A. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010, 28:17-28.
205. Wang H., Zou J., Zhao B., Johannsen E., Ashworth T., Wong H., Pear W.S., Schug J., Blacklow S.C., Arnett K.L., et al. Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells. Proc. Natl. Acad. Sci. USA 2011, 108:14908-14913.
206. Wang N.J., Sanborn Z., Arnett K.L., Bayston L.J., Liao W., Proby C.M., Leigh I.M., Collisson E.A., Gordon P.B., Jakkula L., et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 2011, 108:17761-17766.
207. Wang Y., Liu Y., Malek S.N., Zheng P., Liu Y. Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011, 8:399-411.
208. Weijzen S., Rizzo P., Braid M., Vaishnav R., Jonkheer S.M., Zlobin A., Osborne B.A., Gottipati S., Aster J.C., Hahn W.C., et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat. Med. 2002, 8:979-986.
209. Weissmann S., Roller A., Jeromin S., Hernández M., Abáigar M., Hernández-Rivas J.M., Grossmann V., Haferlach C., Kern W., Haferlach T., et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 2013, 27:2393-2396.
210. Weng A.P., Ferrando A.A., Lee W., Morris J.P., Silverman L.B., Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C. Activating mutations of NOTCH1 in human Tcell acute lymphoblastic leukemia. Science 2004, 306:269-271.
211. Weng A.P., Millholland J.M., Yashiro-Ohtani Y., Arcangeli M.L., Lau A., Wai C., Del Bianco C., Rodriguez C.G., Sai H., Tobias J., et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006, 20:2096-2109.
212. Westhoff B., Colaluca I.N., D'Ario G., Donzelli M., Tosoni D., Volorio S., Pelosi G., Spaggiari L., Mazzarol G., Viale G., et al. Alterations of the Notch pathway in lung cancer. Proc. Natl. Acad. Sci. USA 2009, 106:22293-22298.
213. Wharton K.A., Johansen K.M., Xu T., Artavanis-Tsakonas S. Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing EGF-like repeats. Cell 1985, 43:567-581.
214. Wickremasinghe R.G., Prentice A.G., Steele A.J. p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies. Leukemia 2011, 25:1400-1407.
215. Wilson J.J., Kovall R.A. Crystal structure of the CSL-Notch-Mastermind ternary complex bound to DNA. Cell 2006, 124:985-996.
216. Wu L., Aster J.C., Blacklow S.C., Lake R., Artavanis-Tsakonas S., Griffin J.D. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat. Genet. 2000, 26:484-489.
217. Wu Y., Cain-Hom C., Choy L., Hagenbeek T.J., de Leon G.P., Chen Y., Finkle D., Venook R., Wu X., Ridgway J., et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010, 464:1052-1057.
218. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., Ito S., Yang C., Wang P., Xiao M.T., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
219. Xu K., Usary J., Kousis P.C., Prat A., Wang D.Y., Adams J.R., Wang W., Loch A.J., Deng T., Zhao W., et al. Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. Cancer Cell 2012, 21:626-641.
220. Yan M., Callahan C.A., Beyer J.C., Allamneni K.P., Zhang G., Ridgway J.B., Niessen K., Plowman G.D. Chronic DLL4 blockade induces vascular neoplasms. Nature 2010, 463:E6-E7.
221. Yang Y., Ahn Y.H., Gibbons D.L., Zang Y., Lin W., Thilaganathan N., Alvarez C.A., Moreira D.C., Creighton C.J., Gregory P.A., et al. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J.Clin. Invest. 2011, 121:1373-1385.
222. Yao D., Huang Y., Huang X., Wang W., Yan Q., Wei L., Xin W., Gerson S., Stanley P., Lowe J.B., Zhou L. Protein O-fucosyltransferase 1 (Pofut1) regulates lymphoid and myeloid homeostasis through modulation of Notch receptor ligand interactions. Blood 2011, 117:5652-5662.
223. Yatim A., Benne C., Sobhian B., Laurent-Chabalier S., Deas O., Judde J.G., Lelievre J.D., Levy Y., Benkirane M. NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function. Mol. Cell 2012, 48:445-458.
224. Yeung T.M., Gandhi S.C., Bodmer W.F. Hypoxia and lineage specification of cell line-derived colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 2011, 108:4382-4387.
225. Zagouras P., Stifani S., Blaumueller C.M., Carcangiu M.L., Artavanis-Tsakonas S. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc. Natl. Acad. Sci. USA 1995, 92:6414-6418.
226. Zender S., Nickeleit I., Wuestefeld T., Sörensen I., Dauch D., Bozko P., El-Khatib M., Geffers R., Bektas H., Manns M.P., et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell 2013, 23:784-795.
227. Zeng Q., Li S., Chepeha D.B., Giordano T.J., Li J., Zhang H., Polverini P.J., Nor J., Kitajewski J., Wang C.Y. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 2005, 8:13-23.
228. Zhang K., Wong P., Zhang L., Jacobs B., Borden E.C., Aster J.C., Bedogni B. A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth. Oncogene 2012, 31:4609-4618.
229. Zheng Y., de la Cruz C.C., Sayles L.C., Alleyne-Chin C., Vaka D., Knaak T.D., Bigos M., Xu Y., Hoang C.D., Shrager J.B., et al. A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. Cancer Cell 2013, 24:59-74.
230. Zhou B.B., Peyton M., He B., Liu C., Girard L., Caudler E., Lo Y., Baribaud F., Mikami I., Reguart N., et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006, 10:39-50.
231. Zhou L., Zhang N., Song W., You N., Li Q., Sun W., Zhang Y., Wang D., Dou K. The significance of Notch1 compared with Notch3 in high metastasis and poor overall survival in hepatocellular carcinoma. PLoS ONE 2013, 8:e57382.
232. Zhu J., Wang J., Shi Z., Franklin J.L., Deane N.G., Coffey R.J., Beauchamp R.D., Zhang B. Deciphering genomic alterations in colorectal cancer through transcriptional subtype-based network analysis. PLoS ONE 2013, 8:e79282.
233. Zweidler-McKay P.A., He Y., Xu L., Rodriguez C.G., Karnell F.G., Carpenter A.C., Aster J.C., Allman D., Pear W.S. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood 2005, 106:3898-3906.